|
【结 构 式】 
|
【分子编号】19934 【品名】(2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoic acid 【CA登记号】 |
【 分 子 式 】C21H23NO4 【 分 子 量 】353.41796 【元素组成】C 71.37% H 6.56% N 3.96% O 18.11% |
合成路线1
该中间体在本合成路线中的序号：(IV),(V)The monocyclic peptide precursor (XVIII) was prepared by solid-phase peptide synthesis by two different sequences. In the first one, N-Fmoc-L-leucine (IV) was linked to chlorotrityl resin, and the resultant resin-bound Fmoc-leucine (V) was subsequently deprotected by treatment with piperidine in DMF. To the deprotected leucine-resin (VI) was attached the diaminopropionic acid derivative (III), using either dicyclohexylcarbodiimide or diisopropylcarbodiimide as the coupling reagents, to yield the dipeptide resin (VII), which was further deprotected to (VIII) by means of piperidine in DMF.
| 【1】 Aimoto, S.; Akaji, K.; Synthesis of MEN11420, a glycosylated bicyclic peptide, by intramolecular double cyclization using a chloroimidazolinium coupling reagent. Tetrahedron 2001, 57, 9, 1749. |
| 【2】 Arcamone, F.; Maggi, C.A.; Quartara, L.; Giannotti, D. (Menarini Industrie Farma Riunite Srl); Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compsn.. JP 1999501643; WO 9628467 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (IV),(V) | 19934 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoic acid | C21H23NO4 | 详情 | 详情 | |
| (III) | 56121 | (2S)-3-[(tert-butoxycarbonyl)amino]-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}propanoic acid | C23H26N2O6 | 详情 | 详情 | |
| (VI) | 26057 | L-Leucine | 61-90-5 | C6H13NO2 | 详情 | 详情 |
| (VII) | 56122 | (2S)-2-[((2S)-3-[(tert-butoxycarbonyl)amino]-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}propanoyl)amino]-4-methylpentanoic acid | C29H37N3O7 | 详情 | 详情 | |
| (VIII) | 56123 | (2S)-2-({(2S)-2-amino-3-[(tert-butoxycarbonyl)amino]propanoyl}amino)-4-methylpentanoic acid | C14H27N3O5 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(IX)Title compound was synthesized by solid phase peptide synthesis on a Wang resin using N-9-fluorenylmethoxycarbonyl (Fmoc)-protected amino acids. The (Fmoc)alanine-resin (I) was treated with piperidine in N-methylpyrrolidone to yield deprotected alanine-resin (II). Then, condensation with (Fmoc)-phenylalanine (III) using diisopropyl cabodiimide (DIC) and 1-hydroxybenzotriazole (HOBt) as the coupling reagents provided the (Fmoc)-dipeptide resin (IV), which was deprotected as before with piperidine in NMP. The resulting deprotected dipeptide resin (V) was submitted to further sequential amino acid coupling and deprotection cycles with (Fmoc)-phenylalanine (III), (Fmoc)-valine (VII), and (Fmoc)-leucine (IX), to yield in turn resins (VI), (VIII), and (X), respectively. Resin (X) was then coupled with cholic acid (XI) in the presence of DIC and HOBt to give the corresponding amide (XII).
| 【1】 Reed, M.J.; Hundal, A.; Molineaux, S.; Chin, J.; Kelley, M.; Findeis, M.A.; Kasman, L.; Benjamin, H.; Kubasek, W.; Musso, G.; Signer, E.R.; Wakefield, J.; Lee, J.-J.; Garnick, M.B.; Gefter, M.L. (Praecis Pharmaceuticals Inc.); Modulators of amyloid aggregation. JP 1999514333; WO 9628471 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 19926 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]propionic acid | C18H17NO4 | 详情 | 详情 | |
| (II) | 10141 | D-Alanine; D-2-Aminopropionic Acid | 338-69-2 | C3H7NO2 | 详情 | 详情 |
| (III) | 19030 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-phenylpropionic acid; N-((9H-fluoren-9-ylmethoxy)carbonyl)-phenylalanine | 35661-40-6 | C24H21NO4 | 详情 | 详情 |
| (IV) | 19929 | (2S)-2-[((2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-phenylpropanoyl)amino]propionic acid | C27H26N2O5 | 详情 | 详情 | |
| (V) | 19930 | (2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propionic acid | 3918-87-4 | C12H16N2O3 | 详情 | 详情 |
| (VI) | 19931 | (2S)-2-[((2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl)amino]propionic acid | C21H25N3O4 | 详情 | 详情 | |
| (VII) | 19932 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-methylbutyric acid | C20H21NO4 | 详情 | 详情 | |
| (VIII) | 19933 | (2S)-2-([(2S)-2-[((2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-phenylpropanoyl)amino]-3-phenylpropanoyl]amino)propionic acid | C26H34N4O5 | 详情 | 详情 | |
| (IX) | 19934 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoic acid | C21H23NO4 | 详情 | 详情 | |
| (X) | 19935 | (2S,5S,8S,11S,14S)-14-amino-5,8-dibenzyl-11-isopropyl-2,16-dimethyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazaheptadecan-1-oic acid | C32H45N5O6 | 详情 | 详情 | |
| (XI) | 19936 | (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid | C24H40O5 | 详情 | 详情 | |
| (XII) | 19937 | (2S,5S,8S,11S,14S,19R)-5,8-dibenzyl-14-isobutyl-11-isopropyl-2-methyl-4,7,10,13,16-pentaoxo-19-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-3,6,9,12,15-pentaazaicosan-1-oic acid | C56H83N5O10 | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号：(XII)The coupling and deprotection cycles were continued with leucine (XII), N(in)-Boc-tryptophan (XIV), and again N(in)-Boc-tryptophan (XIV) affording peptide resins (XIII), (XV) and (XVI).
| 【1】 Aldrich, J.V.; Murray, T.F.; Wan, Q.; A novel acetylated analogue of dynorphin A-(1-11) amide as a kappa-opioid receptor antagonist. J Med Chem 1999, 42, 16, 3011. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XI) | 34768 | tert-butyl (5S)-6-amino-5-({[(2S)-1-((2S,5R,8S,11S)-11-amino-16-imino-2,8-bis{3-[(imino{[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]amino}methyl)amino]propyl}-5-methyl-4,7,10-trioxo-16-{[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]amino}-3,6,9,15-tetraazahexadec-1-anoyl)pyrrolidinyl]carbonyl}amino)-6-oxohexylcarbamate | C76H119N17O17S3 | 详情 | 详情 | |
| (XII) | 19934 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoic acid | C21H23NO4 | 详情 | 详情 | |
| (XII) | 34769 | tert-butyl (5S)-6-amino-5-({[(2S)-1-((2S,5R,8S,11S,14S)-14-amino-2,8,11-tris{3-[(imino{[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]amino}methyl)amino]propyl}-5,16-dimethyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazaheptadec-1-anoyl)pyrrolidinyl]carbonyl}amino)-6-oxohexylcarbamate | C82H130N18O18S3 | 详情 | 详情 | |
| (XIV) | 34770 | (2S)-2-[(tert-butoxycarbonyl)[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-(1H-indol-3-yl)propionic acid | C31H30N2O6 | 详情 | 详情 | |
| (XV) | 34771 | tert-butyl 3-((2S,5S,8S,11S,14R,17S)-2-amino-17-({(2S)-2-[({(1S)-1-(aminocarbonyl)-5-[(tert-butoxycarbonyl)amino]pentyl}amino)carbonyl]pyrrolidinyl}carbonyl)-22-imino-8,11-bis{3-[(imino{[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]amino}methyl)amino]propyl}-5-isobutyl-14-methyl-3,6,9,12,15-pentaoxo-22-{[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]amino}-4,7,10,13,16,21-hexaazadocos-1-yl)-1H-indole-1-carboxylate | C98H148N20O21S3 | 详情 | 详情 | |
| (XVI) | 34772 | C114H166N22O24S3 | 详情 | 详情 |
合成路线4
该中间体在本合成路线中的序号：(I)The solid-phase method of peptide synthesis, with an ABIMED AMS 422 synthesizer and a Rink amide resin have been used. N-Fmoc-L-Leucine (I) was attached to Rink amide resin using benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate as the coupling reagent, and the Fmoc protecting group was subsequently removed to afford resin (II). Further coupling and deprotection cycles with N-Fmoc-L-tyrosine(O-t--Bu) (III), N-Fmoc-N-Boc-L-lysine (V) and again N-Fmoc-N-Boc-L-lysine (V) provided peptide resins (IV), (VI) and (VII), respectively.
| 【1】 Davidson, A.; Fridkin, M.; Perl, O.; Rubinraut, S.; Gozes, I.; Ashur-Fabian, O.; Giladi, E.; Mapping the active site in vasoactive intestinal to a core of four amino acids: Neuroprotective drug design. Proc Natl Acad Sci USA 1999, 96, 7, 4143. |
| 【2】 Gozes, I.; Fridkin, M. (Yeda Research & Development Co. Ltd.); Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (VIP). WO 9740070 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 19934 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoic acid | C21H23NO4 | 详情 | 详情 | |
| (II) | 27091 | (2S)-2-amino-4-methylpentanamide | C6H14N2O | 详情 | 详情 | |
| (III) | 18858 | (2S)-3-[4-(tert-butoxy)phenyl]-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]propionic acid | C28H29NO5 | 详情 | 详情 | |
| (IV) | 27096 | (2S)-2-([(2S)-2-amino-3-[4-(tert-butoxy)phenyl]propanoyl]amino)-4-methylpentanamide | C19H31N3O3 | 详情 | 详情 | |
| (V) | 18854 | (2S)-6-[(tert-butoxycarbonyl)amino]-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]hexanoic acid | C26H32N2O6 | 详情 | 详情 | |
| (VI) | 27092 | tert-butyl (5S)-5-amino-6-([(1S)-2-[[(1S)-1-(aminocarbonyl)-3-methylbutyl]amino]-1-[4-(tert-butoxy)benzyl]-2-oxoethyl]amino)-6-oxohexylcarbamate | C30H51N5O6 | 详情 | 详情 |
合成路线5
该中间体在本合成路线中的序号：(III)The title compound was obtained by the solid-phase method using a peptide synthesizer. Starting from Fmoc-valine linked to Wang resin (I), cleavage of the Fmoc group with piperidine in DMF provided the deprotected valine-resin (II), which was then coupled with Fmoc-leucine (III) by means of 1-hydroxybenzotriazole and diisopropylcarbodiimide. The resulting dipeptide resin (IV) was deprotected with piperidine in DMF to give (V), and further coupling with protected serine (VI) yielded (VII). After Fmoc-deprotection, the tripeptide-resin (VIII) was coupled with phenyl isocyanate (IX), affording urea (X). Cleavage from the resin with simultaneous deprotection using trifluoroacetic acid furnished the tripeptide urea (XI). This was finally esterified by treatment with ethanolic HCl to provide the target ethyl ester.
| 【1】 Sawa, E.; et al.; Structural modification of Fas C-terminal tripeptide and its effects on the inhibitory activity of Fas/FAP-1 binding. J Med Chem 1999, 42, 17, 3289. |
| 【2】 Kataoka, S.; Nishitoba, T.; Takahashi, M.; Sawa, E.; Kamishohara, M. (Kirin Brewery Co., Ltd.); Novel peptide cpds. and medicinal compsns. thereof. JP 1999171896; WO 9711091 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 19932 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-methylbutyric acid | C20H21NO4 | 详情 | 详情 | |
| (II) | 21056 | (R)-(-)-Valine; D-Valine; (R)-alpha-Aminoisovaleric acid | 640-68-6 | C5H11NO2 | 详情 | 详情 |
| (III) | 19934 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoic acid | C21H23NO4 | 详情 | 详情 | |
| (IV) | 33117 | (2S)-2-[((2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoyl)amino]-3-methylbutyric acid | C26H32N2O5 | 详情 | 详情 | |
| (V) | 33123 | (2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutyric acid | 35436-83-0 | C11H22N2O3 | 详情 | 详情 |
| (VI) | 33118 | (2S)-3-(tert-butoxy)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]propionic acid | 71989-33-8 | C22H25NO5 | 详情 | 详情 |
| (VII) | 33119 | (5S,8S,11S)-5-(tert-butoxymethyl)-1-(9H-fluoren-9-yl)-8-isobutyl-11-isopropyl-3,6,9-trioxo-2-oxa-4,7,10-triazadodecan-12-oic acid | C33H45N3O7 | 详情 | 详情 | |
| (VIII) | 33120 | (2S)-2-[((2S)-2-[[(2S)-2-amino-3-(tert-butoxy)propanoyl]amino]-4-methylpentanoyl)amino]-3-methylbutyric acid | C18H35N3O5 | 详情 | 详情 | |
| (IX) | 11289 | 1-Isocyanatobenzene; phenyl isocyanate; Phenylisocyanate | 103-71-9 | C7H5NO | 详情 | 详情 |
| (X) | 33121 | (2S)-2-[((2S)-2-[[(2S)-2-[(anilinocarbonyl)amino]-3-(tert-butoxy)propanoyl]amino]-4-methylpentanoyl)amino]-3-methylbutyric acid | C25H40N4O6 | 详情 | 详情 | |
| (XI) | 33122 | (2S)-2-[[(2S)-2-([(2S)-2-[(anilinocarbonyl)amino]-3-hydroxypropanoyl]amino)-4-methylpentanoyl]amino]-3-methylbutyric acid | C21H32N4O6 | 详情 | 详情 |
合成路线6
该中间体在本合成路线中的序号：(VIII)The title compound was prepared by solid phase peptide synthesis. The dioxoborolane-linked resin (XI) was obtained as shown in Scheme 1. 3,7-Dimethyl-6-octenoic acid (I) was protected as the tert-butyl ester (II) by treatment with isobutylene and sulfuric acid, and subsequently oxidized with KMnO4 to afford the hydroxy ketone (III). Addition of methylmagnesium bromide to the keto group of (III) provided diol (IV), which upon reaction with dichloromethyl diisopropoxyborane furnished dioxaborolane (V). Displacement of one chlorine group of (V) with ethylmagnesium bromide at -78 C gave rise to the chloropropyl dioxaborolane (VI). The remaining chlorine atom of (VI) was displaced with lithium bis(trimethylsilyl)amide to yield, after acid desilylation, amine (VII). This was coupled with N-Fmoc-L-leucine (VIII) via the mixed anhydride with isobutyl chloroformate to give amide (IX). After cleavage of the tert-butyl ester of (IX) with trifluoroacetic acid, the resulting carboxylic acid (X) was coupled to the 4-methylbenzhydrylamine resin by means of 2-benzotriazolyl-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), yielding resin (XI).
| 【1】 Dunsdon, R.M.; et al.; Solid phase synthesis of aminoboronic acids: Potent inhibitors of the hepatitis C virus NS3 proteinase. Bioorg Med Chem Lett 2000, 10, 14, 1577. |
| 【2】 Attwood, M.R.; Hurst, D.N.; Jones, P.S.; Kay, P.B.; Raynham, T.M.; Wilson, F.X. (F. Hoffmann-La Roche AG); Antiviral peptide derivs.. JP 2000508344; WO 9822496 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 43339 | 3,7-dimethyl-6-octenoic acid | 502-47-6 | C10H18O2 | 详情 | 详情 |
| (II) | 43340 | tert-butyl 3,7-dimethyl-6-octenoate | C14H26O2 | 详情 | 详情 | |
| (III) | 43341 | tert-butyl 7-hydroxy-3,7-dimethyl-6-oxooctanoate | C14H26O4 | 详情 | 详情 | |
| (IV) | 43342 | tert-butyl 6,7-dihydroxy-3,6,7-trimethyloctanoate | C15H30O4 | 详情 | 详情 | |
| (V) | 43343 | tert-butyl 5-[2-(dichloromethyl)-4,5,5-trimethyl-1,3,2-dioxaborolan-4-yl]-3-methylpentanoate | C16H29BCl2O4 | 详情 | 详情 | |
| (VI) | 43344 | tert-butyl 5-[2-(1-chloropropyl)-4,5,5-trimethyl-1,3,2-dioxaborolan-4-yl]-3-methylpentanoate | C18H34BClO4 | 详情 | 详情 | |
| (VII) | 43345 | tert-butyl 5-[2-(1-aminopropyl)-4,5,5-trimethyl-1,3,2-dioxaborolan-4-yl]-3-methylpentanoate | C18H36BNO4 | 详情 | 详情 | |
| (VIII) | 19934 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoic acid | C21H23NO4 | 详情 | 详情 | |
| (IX) | 43346 | tert-butyl 5-(2-[1-[((2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoyl)amino]propyl]-4,5,5-trimethyl-1,3,2-dioxaborolan-4-yl)-3-methylpentanoate | C39H57BN2O7 | 详情 | 详情 | |
| (X) | 43347 | 5-(2-[1-[((2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoyl)amino]propyl]-4,5,5-trimethyl-1,3,2-dioxaborolan-4-yl)-3-methylpentanoic acid | C35H49BN2O7 | 详情 | 详情 | |
| (XI) | 43348 | 9H-fluoren-9-ylmethyl (1S)-1-[([1-[4-(5-amino-3-methyl-5-oxopentyl)-4,5,5-trimethyl-1,3,2-dioxaborolan-2-yl]propyl]amino)carbonyl]-3-methylbutylcarbamate | C35H50BN3O6 | 详情 | 详情 |
合成路线7
该中间体在本合成路线中的序号：(X)N-Fmoc-L-leucine (X) was coupled to the resin (IX) by means of TBTU to afford, after Fmoc deprotection with piperidine/DMF, the dipeptide-resin (XI). Sequential chain elongation by coupling with the following protected amino acids: Fmoc-3-methyl-L-valine (A), Fmoc-2-methyl-L-phenylalanine (B), Fmoc-L-glutamic gamma-tert-butyl ester (C), and Fmoc-L-aspartic beta-tert-butyl ester (D), followed by the corresponding Fmoc deprotection steps, furnished the peptide resins (XII), (XIII), (XIV) and (XV), respectively.
| 【1】 Jones, P.S.; Kay, P.B.; Wilson, F.X.; Raynham, T.M.; Hurst, D.N. (Hoffmann-La Roche, Inc.); alpha-Ketoamide derivs.. US 6187905 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (B) | 22255 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-(2-methylphenyl)propionic acid | C25H23NO4 | 详情 | 详情 | |
| (D) | 22260 | (2S)-4-(tert-butoxy)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-oxobutyric acid | C23H25NO6 | 详情 | 详情 | |
| (A) | 43350 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3,3-dimethylbutyric acid | 132684-60-7 | C21H23NO4 | 详情 | 详情 |
| (IX) | 47880 | (2S,3S)-3-amino-2-hydroxyheptanamide | C7H16N2O2 | 详情 | 详情 | |
| (X) | 19934 | (2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methylpentanoic acid | C21H23NO4 | 详情 | 详情 | |
| (XI) | 47882 | (2S,3S)-3-[[(2S)-2-amino-4-methylpentanoyl]amino]-2-hydroxyheptanamide | C13H27N3O3 | 详情 | 详情 | |
| (XII) | 47883 | (2S,3S)-3-[((2S)-2-[[(2S)-2-amino-3,3-dimethylbutanoyl]amino]-4-methylpentanoyl)amino]-2-hydroxyheptanamide | C19H38N4O4 | 详情 | 详情 | |
| (XIII) | 47884 | (2S,3S)-3-([(2S)-2-[((2S)-2-[[(2S)-2-amino-3-(2-methylphenyl)propanoyl]amino]-3,3-dimethylbutanoyl)amino]-4-methylpentanoyl]amino)-2-hydroxyheptanamide | C29H49N5O5 | 详情 | 详情 | |
| (XIV) | 47885 | tert-butyl (4S,7S,10S,13S,16S)-4-amino-16-[(1S)-2-amino-1-hydroxy-2-oxoethyl]-10-(tert-butyl)-13-isobutyl-7-(2-methylbenzyl)-5,8,11,14-tetraoxo-6,9,12,15-tetraazaicosan-1-oate | C38H64N6O8 | 详情 | 详情 | |
| (XV) | 47886 | tert-butyl (3S,6S,9S,12S,15S,18S)-3-amino-18-[(1S)-2-amino-1-hydroxy-2-oxoethyl]-6-[3-(tert-butoxy)-3-oxopropyl]-12-(tert-butyl)-15-isobutyl-9-(2-methylbenzyl)-4,7,10,13,16-pentaoxo-5,8,11,14,17-pentaazadocosan-1-oate | C46H77N7O11 | 详情 | 详情 | |
| (C) | 22258 | (2S)-5-(tert-butoxy)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-5-oxopentanoic acid | 104091-08-9 | C24H27NO6 | 详情 | 详情 |